Experimental investigations have further elucidated the tumor-suppressor role of DNASE1L3 in HCC, DNASE1L3 exerts its anti-HCC effects by impeding glycolysis (Xiao, et al., 2022) and impairing the advancement of the cell cycle by integrating with CDK2 (Sun, et al., 2022). Here, CDK2 is linked to hepatocellular carcinoma.